Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH

Launched by COORDINACIÓN DE INVESTIGACIÓN EN SALUD, MEXICO · Jul 22, 2019

Keywords

ClinConnect Summary

Background. Persistent pulmonary hypertension of the newborn (PPHN), is a syndrome characterized by difficulty to provide normal pulmonary vasodilatation at birth or after birth, which may be related to right ventricular dysfunction, congenital diaphragmatic hernia, sepsis, and meconium aspiration. This condition is understudied. PPHN causes pulmonary vascular resistance (PVR) that decreases left pulmonary artery flow (LPA), meaning that blood cannot be oxygenated in the lungs, leading to low oxygen delivery to all organs. Expensive medication along with ventilator support may help, but the...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Plan to administrate TPN for at least 7 days
• • Clinical, gasometric, and echocardiographic diagnosis of congenital diaphragmatic hernia.
• • Gestational age \>=34 weeks.
• • Written informed consent signed by both parents after an explanation of the objectives, procedures and possible risks and benefits of the research, along with the signature of two witnesses
• Exclusion Criteria:
• • Diagnosis of complex congenital cardiopathy
• • Cyanotic congenital cardiology defect
• • Insufficiency of the tricuspid valve
• • Immunosuppressive disease. HIV has been associated with PPHN and human herpesvirus with vascular remodeling, perivascular macrophages, and lung fibrosis
• • Clinical entities that preclude the total parenteral nutrition for one day or longer.
• • Presence of profuse and persistent haemorrhage at any level
• • Elimination criteria
• • Parents who withdraw their consent.
• • Starting a drug at doses for nonclotting treatment such as heparin, enoxaparin.
• • Development of profuse and persistent haemorrhage at any level after receiving vitamin K treatment.